Interleukin-6 and the network of several cytokines in multiple myeloma: An overview of clinical and experimental data

Cytokine

Volumn 16, Issue 3, 2001, Pages 79-86

  Lauta, Vito Michele ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Cytokines; Interleukin 6; Multiple myeloma

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; CORTICOSTEROID; CYTOKINE; ESTROGEN; GENE PRODUCT; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT;

CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; HUMAN; IMMUNOTHERAPY; MAINTENANCE THERAPY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME;

EID: 0035824188     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.2001.0982     Document Type: Review

References (75)

1. Molecular follow-up after allogeneic or autologous transplantation for multiple myeloma
2. Prognostic factors in multiple myeloma
3. Multiple myeloma
4. Interferon and multiple myeloma
5. The use of interferon in the treatment of haematologic malignancies
6. Pharmacological elements in clinical application of synthetic peptides
7. Cytokine network in human multiple myeloma
8. Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease
9. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U-266
10. Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease
11. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6
12. Establishment and characterization of four myeloma cell lines which are responsive to interleukin-6 for their growth
13. Role of interleukin-6 in the growth of myeloma-derived cell lines
14. Heterogeneity in response to interleukin-6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines
15. Interleukin-6 in multiple myeloma and related plasma cell dyscrasias
16. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma
17. Multiple myeloma cell adhesion induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-Kβ
18. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures
19. Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies
20. Interleukin-6 (IL-6) and its receptor (IL-6R) in myeloma-plasmacytoma
21. Interleukin-6 in biology and medicine
22. Interleukin-6 prevents dexamethasone-induced myeloma cell death
23. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or IL-6-mediated up-regulation of bcl-XL11
24. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein
25. IFNα induces autocrine production of IL-6 in myeloma cell lines
26. Inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6 receptor expression in vitro
27. Effects of interleukin-3 and interleukin-6 on peripheral blood cells from multiple myeloma patients and their clinical significance
28. Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression
29. Tumor necrosis factor-α and interleukin-4 promote the differentiation of myeloma cell precursors in multiple myeloma
30. Tumor necrosis factor-α and interleukin-4 in myeloma cell precursor differentiation
31. Human B lymphocytes: Phenotype, proliferation and differentiation
32. Cytokines involved in the progression of multiple myeloma
33. Lack of a role of interleukin 11 in the growth of multiple myeloma
34. Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors
35. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: Correlation with disease activity and other prognostic parameters
36. Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma
37. Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumor cell mass parameters in multiple myeloma
38. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma
39. Interleukin-6 is a prognostic factor in multiple myeloma
40. Determination of IL6, IL1 and IL4 in the plasma of patients with multiple myeloma
41. High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma
42. Interleukin-6 serum levels in patients with multiple myeloma
43. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity
44. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma
45. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma
46. A disturbance of the IL-2/IL-2 receptor systems parallels the activity of multiple myeloma
47. Novel CD28 - Responsive enhancer activated by CREB/AFT and AP-1 families in the human interleukin-2 receptor alpha-chain locus
48. Compensatory effect of TFN alpha on low natural killer activity in the elderly
49. +T cells in tumor from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer
50. + thymocytes and peripheral T cells have immune supressive activity in vitro
51. + regulatory T cells from human peripheral blood
52. Tolerance to islet auto-antigens in type I diabetes
53. Serum interleukin-10 in early stage multiple myeloma
54. Serum interleukin-10 in plasma cell dyscrasias
55. Glucocorticoids inhibit the production of IL-6 from monocytes, endothelial cells and fibroblasts
56. Modification of proinflammatory production by the antirheumatic agents Tenidap and Naproxen. A possible correlate with clinical acute phase response
57. Multiple myeloma: Intensified maintenance therapy with recombinant interferon-α-2b plus glucocorticoids
58. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: A Southwest Oncology Group Study
59. Interleukin-6 fused to mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma
60. Differential sensitivity of human myeloma cell lines and bone marrow colony forming cells to a recombinant diphtheria toxin interleukin-6 fusion protein
61. Mouse plasmacytoma growth in vivo: Enhancement by IL-6 and inhibition by antibodies directed against IL-6 or its receptor
62. Anti-human IL-6 receptor antibody inhibits human myeloma growth in vivo
63. Interleukin-6 in human multiple myeloma
64. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells
65. Maintenance treatment with recombinant interferon alpha-2b in patients with multiple myeloma responding to conventional induction chemotherapy
66. Interferon alpha 2b vs no maintenance therapy during the plateau-phase in multiple myeloma
67. Maintenance therapy with alpha interferon following first line VAD in multiple myeloma
68. Adjuvant alpha interferon improves complete remission rates following allogeneic transplantation for multiple myeloma
69. A randomized trial of maintenance interferon following high dose chemotherapy in multiple myeloma: Long-term follow-up results
70. Alpha-Interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: A retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT)
71. Interferon in multiple myeloma
72. Effects of alpha interferon on serum beta-2-microglobulin
73. Phase I-II trial on natural beta interferon in chemoresistant and relapsing multiple myeloma
74. Interferon in multiple myeloma